EP3679053A4 - CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USE - Google Patents

CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USE Download PDF

Info

Publication number
EP3679053A4
EP3679053A4 EP18852912.7A EP18852912A EP3679053A4 EP 3679053 A4 EP3679053 A4 EP 3679053A4 EP 18852912 A EP18852912 A EP 18852912A EP 3679053 A4 EP3679053 A4 EP 3679053A4
Authority
EP
European Patent Office
Prior art keywords
same
high affinity
selective binding
binding conjugate
affinity cxcr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18852912.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3679053A1 (en
Inventor
Junge ZHANG
Liang Zeng Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mainline Biosciences Inc
Original Assignee
Mainline Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mainline Biosciences Inc filed Critical Mainline Biosciences Inc
Publication of EP3679053A1 publication Critical patent/EP3679053A1/en
Publication of EP3679053A4 publication Critical patent/EP3679053A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18852912.7A 2017-09-05 2018-02-17 CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USE Pending EP3679053A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762554354P 2017-09-05 2017-09-05
PCT/US2018/018530 WO2019050564A1 (en) 2017-09-05 2018-02-17 CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USING THE SAME

Publications (2)

Publication Number Publication Date
EP3679053A1 EP3679053A1 (en) 2020-07-15
EP3679053A4 true EP3679053A4 (en) 2021-10-27

Family

ID=65635072

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18852912.7A Pending EP3679053A4 (en) 2017-09-05 2018-02-17 CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USE

Country Status (6)

Country Link
EP (1) EP3679053A4 (ja)
JP (1) JP2020532496A (ja)
KR (2) KR20200043970A (ja)
CN (1) CN111183146A (ja)
CA (1) CA3065086A1 (ja)
WO (1) WO2019050564A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
US20220218852A1 (en) * 2019-04-18 2022-07-14 Provincial Health Services Authority Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy
JP2023516878A (ja) * 2020-01-26 2023-04-21 メインライン バイオサイエンシーズ（シャンハイ）シーオー．，エルティーディ． 同位体標識された選択的ｃｘｃｒ４結合性ペプチドコンジュゲート並びにその作製方法及び使用方法
KR20230133319A (ko) * 2022-02-11 2023-09-19 (주)씨바이오멕스 탄산탈수소효소 ix를 표적으로 하는 펩타이드 리간드,이를 포함하는 펩타이드 구조체 및 이들의 용도
CN114832113B (zh) * 2022-03-22 2023-06-20 重庆医科大学 疏水药物-马来酰亚胺衍生物及其主动载药脂质体和应用
WO2023201435A1 (en) * 2022-04-20 2023-10-26 Provincial Health Services Authority Cxcr4-targeting compounds, and methods of making and using the same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096662A2 (en) * 2006-02-27 2007-08-30 Technische Universität München Cancer imaging and treatment
WO2008150689A1 (en) * 2007-05-30 2008-12-11 Eli Lilly And Company Cyclic peptide cxcr4 antagonists
CN102626522A (zh) * 2012-04-12 2012-08-08 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
US20130079292A1 (en) * 2010-01-26 2013-03-28 Consiglio Nazionale Delle Ricerche Cyclic peptides binding cxcr4 receptor and relative medical and diagnostic uses
US20150050351A1 (en) * 2013-01-02 2015-02-19 Lucia Irene Gonzalez Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis.
US20150218219A1 (en) * 2012-06-06 2015-08-06 Polyphor Ag Beta-hairpin peptidomimetics
WO2015185162A1 (en) * 2014-06-06 2015-12-10 Technische Universität München Modified cyclopentapeptides and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096662A2 (en) * 2006-02-27 2007-08-30 Technische Universität München Cancer imaging and treatment
WO2008150689A1 (en) * 2007-05-30 2008-12-11 Eli Lilly And Company Cyclic peptide cxcr4 antagonists
US20130079292A1 (en) * 2010-01-26 2013-03-28 Consiglio Nazionale Delle Ricerche Cyclic peptides binding cxcr4 receptor and relative medical and diagnostic uses
CN102626522A (zh) * 2012-04-12 2012-08-08 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
US20150218219A1 (en) * 2012-06-06 2015-08-06 Polyphor Ag Beta-hairpin peptidomimetics
US20150050351A1 (en) * 2013-01-02 2015-02-19 Lucia Irene Gonzalez Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis.
WO2015185162A1 (en) * 2014-06-06 2015-12-10 Technische Universität München Modified cyclopentapeptides and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PENG SHENG-BIN ET AL: "Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 14, no. 2, 1 February 2015 (2015-02-01), pages 480 - 490, XP002771606, ISSN: 1538-8514, DOI: 10.1158/1535-7163.MCT-14-0850 *
YAN WANG ET AL: "Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery", CURRENT PHARMACOLOGY REPORTS, vol. 2, no. 1, 4 January 2016 (2016-01-04), pages 1 - 10, XP055747815, DOI: 10.1007/s40495-015-0044-8 *
YASUSHI YOSHIKAWA ET AL: "Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: New insight into CXCR4FC131 interactions", BIORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM , NL, vol. 22, no. 6, 31 January 2012 (2012-01-31), pages 2146 - 2150, XP028402827, ISSN: 0960-894X, [retrieved on 20120208], DOI: 10.1016/J.BMCL.2012.01.134 *

Also Published As

Publication number Publication date
EP3679053A1 (en) 2020-07-15
JP2020532496A (ja) 2020-11-12
KR20200043970A (ko) 2020-04-28
KR20230145543A (ko) 2023-10-17
WO2019050564A1 (en) 2019-03-14
CN111183146A (zh) 2020-05-19
CA3065086A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
EP3679053A4 (en) CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USE
EP3725798A4 (en) BIOACTIVE CONJUGATE, METHOD FOR ITS MANUFACTURING AND USES
EP3732920A4 (en) INTERCELLULAR TRANSFER TECHNOLOGY, APPARATUS AND RELATED PROCESSES
EP3694181A4 (en) SESSION PREPARATION METHOD, DEVICE AND SYSTEM
EP3694257A4 (en) SESSION ESTABLISHMENT PROCESS, DEVICE AND SYSTEM
EP3733715A4 (en) TRIACORPS, ITS PREPARATION PROCESS AND ITS USE
EP3621641A4 (en) ANTI-CD3 BINDING DOMAINS AND ANTIBODIES CONTAINING THEM AND THE METHOD OF MANUFACTURING AND USING THEM
EP3615612A4 (en) THERMOPLASTIC COMPOSITIONS, PROCESS, DEVICE AND USES
EP3648506A4 (en) METHOD, DEVICE AND SYSTEM FOR ACTIVATING A SESSION
EP3720235A4 (en) SESSION PREPARATION METHOD, DEVICE AND SYSTEM
EP3689893A4 (en) IMMUNOGLOBULIN-BINDING PROTEIN AND AFFINITY CARRIERS THEREFORE
EP3704227A4 (en) COMPOSITION AND PROCESS
EP3632907A4 (en) N- (AZAARYL) CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, MANUFACTURING METHOD FOR IT AND USE THEREOF
EP3687540A4 (en) HETEROARYL COMPOUNDS USED AS CXCR4 INHIBITORS, COMPOSITION AND METHOD OF USE THEREOF
EP3617218A4 (en) DIHYDROARTEMISININ STEROID CONJUGATE AND METHOD OF MANUFACTURING AND USES THEREOF
EP3594312A4 (en) COMPOSITION, PROCESS FOR ITS PRODUCTION AND ASSOCIATED USE
EP3720203A4 (en) MEETING SETUP METHOD, DEVICE AND SYSTEM
EP3627322A4 (en) APPLICATION INTERACTION METHOD, INTERACTION METHOD AND DEVICE
EP3398958A4 (en) POLYAMIDIC ACID, PROTEIN POLYAMINOIC ACID CONJUGATE AND MANUFACTURING METHOD THEREFOR
EP3589670A4 (en) ELASTOMER, ITS PREPARATION PROCESS AND ASSOCIATED USE
EP3689894A4 (en) IMMUNOGLOBULIN-BINDING PROTEIN AND AFFINITY CARRIERS THEREFORE
EP3643095A4 (en) METHOD FOR IMPLEMENTING A RLAU METHOD AND DEVICE THEREFOR
EP3585511A4 (en) METAL MOLYBDATE AND METHOD FOR MANUFACTURING THEREOF
EP3699179A4 (en) TRICYCLIC DERIVATIVE CONTAINING PYRAZOLYL, PROCESS FOR PREPARATION AND USE
EP3773520A4 (en) BIOXOME PARTICLES, REDOXOMS, PROCESS AND COMPOSITION

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 7/06 20060101AFI20210621BHEP

Ipc: C07K 7/50 20060101ALI20210621BHEP

Ipc: C07K 5/12 20060101ALI20210621BHEP

Ipc: A61K 38/00 20060101ALI20210621BHEP

Ipc: A61K 49/00 20060101ALI20210621BHEP

Ipc: C07K 14/705 20060101ALI20210621BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20210927

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/705 20060101ALI20210921BHEP

Ipc: A61K 49/00 20060101ALI20210921BHEP

Ipc: A61K 38/00 20060101ALI20210921BHEP

Ipc: C07K 5/12 20060101ALI20210921BHEP

Ipc: C07K 7/50 20060101ALI20210921BHEP

Ipc: C07K 7/06 20060101AFI20210921BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240314